| scholarly article | Q13442814 |
| P50 | author | Joon Jeong | Q57837437 |
| Sung Gwe Ahn | Q60724969 | ||
| P2093 | author name string | Ji-Hae Lee | |
| Woo Ho Kim | |||
| Jeffrey E Green | |||
| Jae Myun Lee | |||
| Seung Ah Lee | |||
| Hak Min Lee | |||
| Hy-De Lee | |||
| Akira Oshima | |||
| Seung Myung Dong | |||
| Seung-Hyun Kwon | |||
| P2860 | cites work | Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence | Q24310163 |
| A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression | Q24314451 | ||
| A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes | Q24647928 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis | Q28236828 | ||
| A new gene with sequence and structural similarity to the gene encoding human lysyl oxidase | Q28299360 | ||
| Triple-Negative Breast Cancer | Q29391607 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| A novel asymmetric 3D in-vitro assay for the study of tumor cell invasion | Q33516890 | ||
| Epithelial to mesenchymal transition and breast cancer. | Q33627118 | ||
| Central nervous system, uterus, heart, and leukocyte expression of the LOXL3 gene, encoding a novel lysyl oxidase-like protein | Q33949334 | ||
| A novel human lysyl oxidase-like gene (LOXL4) on chromosome 10q24 has an altered scavenger receptor cysteine rich domain | Q34100202 | ||
| Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo | Q34187677 | ||
| Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas | Q34197948 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer | Q36449060 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| LOXL2-mediated matrix remodeling in metastasis and mammary gland involution | Q37346579 | ||
| Novel therapeutic approaches to the treatment of metastatic breast cancer | Q37626248 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). | Q37768426 | ||
| The rationale for targeting the LOX family in cancer | Q38027412 | ||
| Receptor activity modifying protein‐3 mediates the protumorigenic activity of lysyl oxidase‐like protein‐2 | Q38341297 | ||
| Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment | Q39659310 | ||
| Functional analysis of LOXL2 in pancreatic carcinoma | Q39763088 | ||
| Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway | Q39822163 | ||
| Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells | Q39866831 | ||
| Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas | Q39971722 | ||
| Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors | Q40152499 | ||
| TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles. | Q41129780 | ||
| The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. | Q54388695 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplastic invasiveness | Q112498967 |
| P304 | page(s) | 89-99 | |
| P577 | publication date | 2013-08-10 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients | |
| P478 | volume | 141 |
| Q90193916 | Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs |
| Q90677904 | Associations between absolute neutrophil count and lymphocyte-predominant breast cancer |
| Q40104569 | Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection |
| Q34422525 | Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer |
| Q38841862 | Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide |
| Q61454345 | Divergent roles of lysyl oxidase family members in ornithine decarboxylase- and RAS-transformed mouse fibroblasts and human melanoma cells |
| Q37520614 | Emerging role of LOXL2 in the promotion of pancreas cancer metastasis |
| Q37269104 | Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression |
| Q92867262 | High A20 expression negatively impacts survival in patients with breast cancer |
| Q51319814 | Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer. |
| Q64234918 | Inhibition of LOXL2 Enhances the Radiosensitivity of Castration-Resistant Prostate Cancer Cells Associated with the Reversal of the EMT Process |
| Q40068242 | Inhibition of Lysyl Oxidase and Lysyl Oxidase-Like Enzymes Has Tumour-Promoting and Tumour-Suppressing Roles in Experimental Prostate Cancer |
| Q92305732 | Interplay Between LOX Enzymes and Integrins in the Tumor Microenvironment |
| Q90642659 | LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype |
| Q93173616 | LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells |
| Q92965702 | LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells |
| Q37707030 | LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer |
| Q38723997 | Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer |
| Q24298337 | Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1 |
| Q58557818 | Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition |
| Q42546578 | Lysyl oxidase‑like 2 is expressed in kidney tissue and is associated with the progression of tubulointerstitial fibrosis. |
| Q38909572 | Orthotopic non-metastatic and metastatic oral cancer mouse models |
| Q39251086 | Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis |
| Q38765720 | Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer. |
| Q45393126 | Role of LOXL2 in the epithelial-mesenchymal transition and colorectal cancer metastasis |
| Q33624937 | Roles of Copper-Binding Proteins in Breast Cancer |
| Q35945328 | Targeting lysyl oxidase for molecular imaging in breast cancer |
| Q92015141 | The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma |
| Q34258373 | The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers |
| Q36498118 | Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma |
| Q38826075 | Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. |